EHJCP: Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease

Background: The global prevalence of type 2 diabetes mellitus (T2DM) in 2019 is estimated to be approximately 500 million

Background: The global prevalence of type 2 diabetes mellitus (T2DM) in 2019 is estimated to be approximately 500 million

For patients with established coronary heart disease and T2DM, the current standard of care for antithrombotic prophylaxis is low-dose aspirin

Objective: To evaluate the health economics of ticagrelor in patients with type 2 diabetes and coronary heart disease from the perspective of multinational payers

Methods and results: A Markov model was developed to infer patient lifetime outcomes

Figure 1 Cost-benefit acceptance curve

Figure 1 Cost-benefit acceptance curve

Table 1

Table 1

Table 2 Hazard ratios associated with ticagrelor treatment

Table 2 Hazard ratios associated with ticagrelor treatment

Conclusions: Ticagrelor plus aspirin may be more cost-effective than aspirin alone in some European countries in patients with T2DM and coronary heart disease without prior myocardial infarction or stroke, according to THEMIS findings

Conclusions: Ticagrelor plus aspirin may be more cost-effective than aspirin alone in some European countries in patients with T2DM and coronary heart disease without prior myocardial infarction or stroke, according to the THEMIS study

Original source: Steg PG, Bhatt DL, James SK, et al.
Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial.
Eur Heart J Cardiovasc Pharmacother 2022 Apr 30 Cost- effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial.


Leave a Comment